ANI Pharmaceuticals ANIP Accrued Government Rebates
Accrued Government Rebates at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept anip:AccruedGovernmentRebates.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's accrued government rebates.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's accrued government rebates?
- ANI Pharmaceuticals (ANIP) reported accrued government rebates of $38.42M in Q1 2026.
- How has ANI Pharmaceuticals's accrued government rebates changed year-over-year?
- ANI Pharmaceuticals's accrued government rebates increased by 69.7% year-over-year, from $22.64M to $38.42M.
- What is the long-term trend for ANI Pharmaceuticals's accrued government rebates?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's accrued government rebates has grown at a 40.7% compound annual growth rate (CAGR), from $7.83M to $43.15M.
- What does accrued government rebates mean?
- This represents the estimated liability for rebates owed to government agencies, such as Medicaid or other public health programs, resulting from the sale of pharmaceutical products. These accruals are necessary to account for mandatory price concessions and discounts required by law. Changes in this balance often reflect shifts in product mix, pricing strategies, or changes in government reimbursement regulations.